Poor Quality Sleep Clinical Trial
— BEDTIMEOfficial title:
Effect of Bioelectrical Impedance Analysis-Guided Comparing With Standard Clinical-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients
NCT number | NCT02825589 |
Other study ID # | ID05-59-12 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | February 2017 |
Verified date | March 2019 |
Source | Mahidol University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Based on many previous data proving hypervolemia in chronic hemodialysis patients could lead to sleep apnea and poor sleep quality. The investigators conduct this trial to evaluate whether more accurate dry weight assessment with BIA in these patients can lead to better sleep quality (measured by sleep actigraphy and questionnaires). The investigators will enroll 30 chronic hemodialysis patients in hemodialysis unit of Ramathibodi hospital whose age > 18 years with subclinical hypervolemic status and baseline Pittsburgh sleep quality index (PSQI) score > 5 into study. Patients with bed-ridden status, alteration of consciousness and unstable hemodynamics will be excluded. Then eligible patients will be randomized into 2 groups, BIA-guided and standard clinical guided dry weight assessment. The investigators will assess participants' dry weight at beginning of study, 3rd month and 6th month. Sleep actigraphy parameters (eg. total sleep time, sleep efficiency), sleep questionnaires score, left ventricular mass index by echocardiography, ambulatory blood pressure monitoring and blood chemistry results were collected at beginning of study, the end of 1st, 3rd and 6th month. The primary outcome is change of sleep actigraphy parameters between the groups. The secondary outcomes are change of sleep questionnaires scores, change of left ventricular mass index, change of ambulatory BP monitoring and also cardiovascular complications between groups.
Status | Completed |
Enrollment | 19 |
Est. completion date | February 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - regular hemodialysis 3 times/week - PSQI score >5 - Subclinical hypervolemia Exclusion Criteria: - bed ridden status - alteration of consciousness - unstable hemodynamics |
Country | Name | City | State |
---|---|---|---|
Thailand | Ramathibodi hospital, Mahidol university | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of sleep actigraphy parameters | total sleep time, sleep efficiency, fragmentation index | 6 months | |
Secondary | Change of PSQI scores | PSQI or Pittsburgh sleep Quality Index is an instrument for assessment subjective sleep quality in various group of patients. | 6 months | |
Secondary | Change of left ventricular mass index by echocardiography | 6 months | ||
Secondary | Change of ambulatory blood pressure monitoring | 6 months | ||
Secondary | Cardiovascular complications | complications which can occur from overestimate of ultrafiltration eg. intradialytic hypotension, arrhythmia, cerebral vascular events, myocardial ischemic events etc. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947673 -
Mechanisms of Intradialytic Hypertension
|
N/A | |
Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
Terminated |
NCT01982864 -
Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
|
Phase 4 | |
Completed |
NCT01448174 -
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT01421771 -
Blood Pressure in Dialysis Patients
|
N/A | |
Completed |
NCT01722695 -
Performance Comparison of Revaclear With Larger Dialyzer
|
N/A | |
Withdrawn |
NCT01015313 -
Effects of Intensified Sodium Management in Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT02452788 -
Pharmaceutical Care in Ambulatory Hemodialysis Patients
|
N/A | |
Completed |
NCT02259413 -
Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis
|
N/A | |
Recruiting |
NCT01356563 -
Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients
|
N/A | |
Completed |
NCT01181544 -
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
|
N/A | |
Completed |
NCT01320202 -
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT02285075 -
Temocillin Pharmacokinetic in Hemodialysis
|
Phase 4 | |
Completed |
NCT00890045 -
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
|
N/A | |
Not yet recruiting |
NCT02264964 -
Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis
|
N/A | |
Terminated |
NCT01312441 -
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
|
Phase 4 | |
Completed |
NCT01214928 -
Hemodialysis Vitamin D Pilot
|
N/A | |
Completed |
NCT00967993 -
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
|
Phase 2 | |
Completed |
NCT01981603 -
Transplant Navigator Dissemination
|
N/A | |
Completed |
NCT01578421 -
Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
|
N/A |